Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Apellis Pharmaceuticals, Inc. | apls-ex322_9.htm |
| EX-32.1 - EX-32.1 - Apellis Pharmaceuticals, Inc. | apls-ex321_13.htm |
| EX-31.2 - EX-31.2 - Apellis Pharmaceuticals, Inc. | apls-ex312_6.htm |
| EX-31.1 - EX-31.1 - Apellis Pharmaceuticals, Inc. | apls-ex311_11.htm |
| EX-23.1 - EX-23.1 - Apellis Pharmaceuticals, Inc. | apls-ex231_8.htm |
| EX-21.1 - EX-21.1 - Apellis Pharmaceuticals, Inc. | apls-ex211_7.htm |
| EX-10.26 - EX-10.26 - Apellis Pharmaceuticals, Inc. | apls-ex1026_87.htm |
| EX-10.25 - EX-10.25 - Apellis Pharmaceuticals, Inc. | apls-ex1025_88.htm |
| EX-10.17 - EX-10.17 - Apellis Pharmaceuticals, Inc. | apls-ex1017_217.htm |
| EX-4.4 - EX-4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES E - Apellis Pharmaceuticals, Inc. | apls-ex44_10.htm |
| 10-K - 10-K - Apellis Pharmaceuticals, Inc. | apls-10k_20201231.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
(1) |
Registration Statements (Form S-3 Nos. 333-235830 and 333-229091) of Apellis Pharmaceuticals, Inc., and |
|
|
(2) |
Registration Statement (Form S-8 No. 333-236710) pertaining to the 2020 Inducement Stock Incentive Plan of Apellis Pharmaceuticals, Inc., and |
|
|
(3) |
Registration Statement (Form S-8 No. 333-236708) pertaining to the 2017 Stock Incentive Plan and Stock Option Inducement Awards (March 2019-February 2020) of Apellis Pharmaceuticals, Inc., and |
|
|
(4) |
Registration Statement (Form S-8 No. 333-229876) pertaining to the 2017 Stock Incentive Plan, Inducement Stock Option Award, and 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc., and |
|
|
(5) |
Registration Statement (Form S-8 No. 333-221528) pertaining to the 2010 Equity Incentive Plan, 2017 Stock Incentive Plan, and 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc.; |
of our report dated February 26, 2019, with respect to the consolidated financial statements of Apellis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Apellis Pharmaceuticals, Inc. for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Boston, Massachusetts
February 25, 2021